| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7879842 | AMGEN INC | Beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Feb, 2026
(2 years from now) | |
| US7361650 | AMGEN INC | γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Feb, 2026
(2 years from now) | |
| US7361649 | AMGEN INC | β-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Feb, 2026
(2 years from now) | |
| US7867996 | AMGEN INC | γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Dec, 2026
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7361649 (Pediatric) | AMGEN INC | β-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Aug, 2026
(2 years from now) | |
|
US7879842 (Pediatric) | AMGEN INC | Beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Aug, 2026
(2 years from now) | |
|
US7361650 (Pediatric) | AMGEN INC | γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Aug, 2026
(2 years from now) | |
|
US7867996 (Pediatric) | AMGEN INC | γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Jun, 2027
(3 years from now) | |
Corlanor is owned by Amgen Inc.
Corlanor contains Ivabradine Hydrochloride.
Corlanor has a total of 8 drug patents out of which 0 drug patents have expired.
Corlanor was authorised for market use on 15 April, 2015.
Corlanor is available in tablet;oral dosage forms.
Corlanor can be used as a method for treating heart failure in a human using a crystalline form of ivabradine hydrochloride.
The generics of Corlanor are possible to be released after 12 June, 2027.
Drugs and Companies using IVABRADINE HYDROCHLORIDE ingredient
Market Authorisation Date: 15 April, 2015
Treatment: A method for treating heart failure in a human using a crystalline form of ivabradine hydrochloride
Dosage: TABLET;ORAL
CORLANOR family patents
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7361650 | AMGEN INC | γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Feb, 2026
(2 years from now) | |
| US7361649 | AMGEN INC | β-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Feb, 2026
(2 years from now) | |
| US7879842 | AMGEN INC | Beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Feb, 2026
(2 years from now) | |
| US7867996 | AMGEN INC | γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Dec, 2026
(3 years from now) | |
Corlanor is owned by Amgen Inc.
Corlanor contains Ivabradine.
Corlanor has a total of 4 drug patents out of which 0 drug patents have expired.
Corlanor was authorised for market use on 22 April, 2019.
Corlanor is available in solution;oral dosage forms.
Corlanor can be used as a method for treating heart failure in a human using a crystalline form of ivabradine hydrochloride.
The generics of Corlanor are possible to be released after 12 December, 2026.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Apr 22, 2026 |
| Pediatric Exclusivity (PED) | Oct 22, 2026 |
Drugs and Companies using IVABRADINE ingredient
Market Authorisation Date: 22 April, 2019
Treatment: A method for treating heart failure in a human using a crystalline form of ivabradine hydrochloride
Dosage: SOLUTION;ORAL
CORLANOR family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic